Author:
Ibarra Manuel,Schiavo Alejandra,Lesko Lawrence J.
Publisher
Springer International Publishing
Reference12 articles.
1. Suarez-Sharp S, Cohen M, Kesisoglou F, et al. Applications of clinically relevant dissolution testing: workshop summary report. AAPS J. 2018;20:1–14. https://doi.org/10.1208/s12248-018-0252-3.
2. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). The use of physiologically based pharmacokinetic analyses – biopharmaceutics applications for oral drug product development, manufacturing changes, and controls. Guidance for Industry (draft). 2020.
3. Bermejo M, Hens B, Dickens J, et al. A mechanistic physiologically-based biopharmaceutics modeling (PBBM) approach to assess the in vivo performance of an orally administered drug product: from IVIVC to IVIVP. Pharmaceutics. 2020;12. https://doi.org/10.3390/pharmaceutics12010074.
4. Jamei M, Abrahamsson B, Brown J, et al. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary. Eur J Pharm Biopharm. 2020; https://doi.org/10.1016/j.ejpb.2020.08.005.
5. Ibarra M, Valiante C, Sopeña P, et al. Integration of in vitro biorelevant dissolution and in silico PBPK model of carvedilol to predict bioequivalence of oral drug products. Eur J Pharm Sci. 2018;118:176–82. https://doi.org/10.1016/j.ejps.2018.03.032.